2020
DOI: 10.1111/codi.15295
|View full text |Cite
|
Sign up to set email alerts
|

Minimally important differences for interpreting the EORTC QLQ‐C30 in patients with advanced colorectal cancer treated with chemotherapy

Abstract: Aim The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) assesses the health-related quality of life of patients in cancer trials. There are currently no minimally important difference (MID) guidelines for the EORTC QLQ-C30 for colorectal cancer (CRC). This study aims to estimate MIDs for the EORTC QLQ-C30 scales in patients with advanced CRC treated with chemotherapy and enrolled in clinical trials. Method The data were obtained from three publis… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

4
49
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 35 publications
(53 citation statements)
references
References 28 publications
4
49
0
Order By: Relevance
“…For example, in general the MCID used for scales of EORTC measures is ≥10 points, but may be too simplistic, as it does not differentiate between the different scales, the direction of change (improvement versus deterioration) and is not applicable to all cancer populations [23,24]. Therefore, for the EORTC QLQ-C30, MCIDs for each scale are currently being developed for different cancer sites [25].…”
Section: Discussionmentioning
confidence: 99%
“…For example, in general the MCID used for scales of EORTC measures is ≥10 points, but may be too simplistic, as it does not differentiate between the different scales, the direction of change (improvement versus deterioration) and is not applicable to all cancer populations [23,24]. Therefore, for the EORTC QLQ-C30, MCIDs for each scale are currently being developed for different cancer sites [25].…”
Section: Discussionmentioning
confidence: 99%
“…These analyses were performed as non-inferiority analyses reporting coefficients with 95% confidence intervals for mean differences and comparing with between-group mean minimal important differences (MID) as reported by Musoro et al [ 40 ]. As it is not assured that the baseline PRO measurements were performed before the patient and healthcare professionals were informed about the result of the randomization, the treatment effect was included at baseline.…”
Section: Methodsmentioning
confidence: 99%
“…In general, each PRO domain was interpreted according to clinically relevant MID using guidelines for between-group differences and changes over time [ 40 , 42 ].…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations